Last reviewed · How we verify
BMS-650032 (Asunaprevir)
Asunaprevir is a hepatitis C virus (HCV) NS3 protease inhibitor that blocks viral protein processing and replication.
Asunaprevir is a hepatitis C virus (HCV) NS3 protease inhibitor that blocks viral protein processing and replication. Used for Chronic hepatitis C virus (HCV) infection, genotype 1b.
At a glance
| Generic name | BMS-650032 (Asunaprevir) |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | HCV NS3 protease inhibitor |
| Target | HCV NS3/4A serine protease |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | Phase 3 |
Mechanism of action
Asunaprevir binds to and inhibits the HCV NS3/4A serine protease, an enzyme essential for cleaving viral polyproteins into functional proteins required for viral replication. By blocking this protease, the drug prevents the maturation of infectious HCV particles and suppresses viral replication in hepatocytes.
Approved indications
- Chronic hepatitis C virus (HCV) infection, genotype 1b
Common side effects
- Fatigue
- Headache
- Nausea
- Diarrhea
- Elevated liver enzymes
Key clinical trials
- Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (PHASE2)
- Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults
- Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy
- Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea
- Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C
- A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1 (PHASE3)
- Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual (PHASE3)
- Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BMS-650032 (Asunaprevir) CI brief — competitive landscape report
- BMS-650032 (Asunaprevir) updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI